Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China

Zou, Zhongqing; Guo, Tingting; Cui, Jian; Tang, Wenjiao; Li, Yan; Wang, Fangfang; Dong, Tian; Yang, Yunfan; Feng, Yan; Ho, Matthew; Zhang, Li; Pan, Ling; Niu, Ting

doi:10.7150/jca.53209



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(9):2633-2642. doi:10.7150/jca.53209 This issue Cite

Research Paper

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China

Zhongqing Zou^1,2#, Tingting Guo^1,3#, Jian Cui¹, Wenjiao Tang¹, Yan Li¹, Fangfang Wang^1,4, Tian Dong¹, Yunfan Yang¹, Yan Feng¹, Matthew Ho⁵, Li Zhang^1✉, Ling Pan¹, Ting Niu¹

1. Department of Hematology, West China Hospital, Sichuan University, China.
2. Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
3. Center for Precision Medicine, West China Hospital, Sichuan University, China.
4. Hematology Research Laboratory, Department of Hematology, West China Hospital, Sichuan University, China.
5. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States.
#These authors contributed equally to this study.

Citation:

Zou Z, Guo T, Cui J, Tang W, Li Y, Wang F, Dong T, Yang Y, Feng Y, Ho M, Zhang L, Pan L, Niu T. Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China. J Cancer 2021; 12(9):2633-2642. doi:10.7150/jca.53209. https://www.jcancer.org/v12p2633.htm

Other styles

Abstract

Multiple myeloma (MM) is a heterogeneous disease that remains incurable with significant interpatient variability in outcomes. Regulatory B cells (Bregs) were observed to be involved into specific defects in MM. Here, we provide our risk-adapted approach to newly diagnosed MM (NDMM), combining with the fundamental dysfunction of Bregs. We reported one hundred consecutive patients with NDMM from South-Western China, primarily treated with bortezomib plus dexamethasone with or without a 3^rd agent, were enrolled from 2017. Bone marrow aspirates were obtained and flow cytometry (FCM) was used to quantify the percentage of Bregs from the bone marrow. The correlation between Bregs and clinical characters were further analyzed. This study found using bortezomib plus dexamethasone as backbone showed promising efficacy with acceptable tolerability in NDMM. The relatively compromised progression free survival (PFS) points to the essential synergy of bortezomib and lenalidomide here. This study also found that altered proportions of Bregs were closely correlated with treatment efficacy and prognosis in MM. Further understanding of Bregs biology might provide new opportunities to develop immunotherapy, which could prove beneficial in treating MM.

Keywords: myeloma, bortezomib, B cell, real world, prognosis

Citation styles

APA

Zou, Z., Guo, T., Cui, J., Tang, W., Li, Y., Wang, F., Dong, T., Yang, Y., Feng, Y., Ho, M., Zhang, L., Pan, L., Niu, T. (2021). Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China. Journal of Cancer, 12(9), 2633-2642. https://doi.org/10.7150/jca.53209.

ACS

Zou, Z.; Guo, T.; Cui, J.; Tang, W.; Li, Y.; Wang, F.; Dong, T.; Yang, Y.; Feng, Y.; Ho, M.; Zhang, L.; Pan, L.; Niu, T. Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China. J. Cancer 2021, 12 (9), 2633-2642. DOI: 10.7150/jca.53209.

NLM

CSE

Zou Z, Guo T, Cui J, Tang W, Li Y, Wang F, Dong T, Yang Y, Feng Y, Ho M, Zhang L, Pan L, Niu T. 2021. Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China. J Cancer. 12(9):2633-2642.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.